Administrative Core

行政核心

• 批准号: 7694038
• 负责人: HARRIET L ROBINSON
• 金额: $ 30.46万
• 依托单位: GEOVAX, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7694038
• 关键词: Accounting; Acquired Immunodeficiency Syndrome; Adjuvant; Africa; Annual Reports; Asia; Biological Assay; Budgets; C-Peptide; CSF2 gene; Cause of Death; Clinical Trials; Consultations; Country; DNA; DNA/MVA vaccine; Data; Ensure; Goals; Granulocyte-Macrophage Colony-Stimulating Factor; HIV-1; Immune response; India; Infection; Intellectual Property; Lead; Leadership; Legal patent; Mediation; Modeling; Mucosal Immune Responses; Numbers; Phase; Publications; Publishing; Quality Control; Records; Resources; South Africa; Southern Africa; T-Lymphocyte; Testing; United States National Institutes of Health; Vaccines; Virus-like particle; concept; data management; doxorubicin/mitomycin/vinblastine protocol; experience; improved; preclinical study; programs; quality assurance; response; vaccine development; vector

The acquired immunodeficiency syndrome (AIDS) caused by HIV-1 is the leading cause of death in Africa and the fourth leading cause of death worldwide. This IPCAVD is developing HIV/AIDS vaccines that use DNA for priming and MVA for boosting (DNA/MVA vaccine) as well as a simpler an ultimately easier to deploy form of these vaccines, the use of MVA for both priming and boosting (MVA/MVA vaccine). Both the DNA and MVA vaccines use single vectors to express virus like particles (VLP). This IPCAVD seeks to build GM-CSF, an adjuvant, into these products for expression in cis. In preclinical studies, co-expression of GMCSF has substantially enhanced protection. A central hypothesis for the IPCAVD is that GM-CSF improves protection by enhancing the mucosal presence of elicited T cell and Ab responses. Clade C HIV-1 which is endemic in southern Africa and parts of Asia accounts for about one half of the infections worldwide and >90% of the cases in India, a country with a rapidly spreading infection that has surpassed South Africa in its total number of cases. The vaccine development effort of this IPCAVD is focused on developing a clade C vaccine for India. This administrative core has five specific aims: ¿ Provide overall co-ordination for the Program ¿ Provide data management and statistical support ¿ Provide logistical support for intellectual property filings and negotiations ¿ Assist with publications ¿ Maintain budgets and fiscal oversight Dr. Harriet Robinson, the Program Director, will lead the Administrative core. She has demonstrated experience in leading IPCAVD programs and moving concepts from the bench to early phase clinical trials through the HVTN.

由 HIV-1 引起的获得性免疫缺陷综合症 (AIDS) 是人类死亡的主要原因 非洲和全球第四大死亡原因 该 IPCVD 正在开发艾滋病毒/艾滋病疫苗。 使用 DNA 进行初免，使用 MVA 进行加强（DNA/MVA 疫苗）以及更简单、更容易接种的疫苗 这些疫苗的部署形式，使用 MVA 进行初免和加强（MVA/MVA 疫苗）。 DNA 和 MVA 疫苗使用单一载体来表达病毒样颗粒 (VLP)。 GM-CSF，一种佐剂，加入到这些产品中以顺式表达。在临床前研究中，GMCSF 的共表达。 IPCVD 的一个中心假设是 GM-CSF 改善了保护作用。 通过增强诱导的 T 细胞和抗体 C 型 HIV-1 的粘膜存在来提供保护。 南部非洲和亚洲部分地区流行，约占全世界感染病例的一半 超过 90% 的病例发生在印度，该国感染传播迅速，感染率已超过南非 该 IPCAVD 的疫苗开发工作重点是开发 C 分支。 印度的疫苗。 该行政核心有五个具体目标： ¿为该计划提供总体协调 ¿提供数据管理和统计支持 ¿为知识产权备案和谈判提供后勤支持 ¿协助出版 ¿维持预算和财政监督 项目总监 Harriet Robinson 博士将领导行政核心。 拥有领先的 IPCVD 项目以及将概念从实验室转移到早期临床试验的经验 通过 HVTN。